Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 11, 2003, Pages 840-841

  Gorlick, Richard ^a   Meyers, Paul A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; LIMB SALVAGE; NOTE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR NECROSIS;

BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; NECROSIS; OSTEOSARCOMA;

EID: 0242440867     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200311000-00003     Document Type: Note

References (4)

1. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
2. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group study POG-8651. J Clin Oncol. 2003;21:1574-1580.
3. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458.
4. Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol. 2003;25:845-853.